Author + information
- Gianluigi Savarese,
- Camilla Hage,
- Ulf Dahlstrom,
- Pasquale Perrone-Filardi,
- Lars Lund and
- Lars H. Lund
In heart failure with preserved ejection fraction (HFPEF), feasible surrogate endpoints are needed for phase II trials. Aim of the current analysis was to assess whether reduction in NT-proBNP predicts improved mortality and morbidity in an unselected population of HFPEF patients.
In the Swedish Heart Failure Registry, HFPEF (EF≥40%) patients reporting at least two consecutive out-patient NT-proBNP assessments were prospectively studied. The association between changes in NT-proBNP and overall mortality, HF hospitalization and their composite was assessed by multivariable Cox regression.
In 654 patients, at a median 7 months, 363 patients (55%) showed an improvement (Δ NT-proBNP0). Over a median follow-up of 2.21 years (IQR 0.92-3.43), improvements in NT-proBNP were significantly associated with a reduction of overall mortality, HF hospitalization and of the composite outcome (hazard ratios for improved vs. worsened NT-proBNP are shown in Table). Predictors of NT-proBNP improvement were speciality care, short-duration HF, EF 40-49% vs. >=50%, higher NYHA class, lung disease, previous myocardial infarction, absent atrial fibrillation, and therapy with angiotensin receptor blockers and aldosterone antagonists.
Improvements in NT-proBNP are associated with improved prognosis in HFPEF. Changes in NT-proBNP could serve as a surrogate endpoint in phase 2 HFPEF trials.
Poster Area, South Hall A1
Sunday, April 03, 2016, 3:45 p.m.-4:30 p.m.
Session Title: Novel Approaches to HFpEF and Other Common Dilemmas
Abstract Category: 26. Heart Failure and Cardiomyopathies: Clinical
Presentation Number: 1217-048
- 2016 American College of Cardiology Foundation